1. PREFACE
  1.1. Scope of the Report
  1.2. Research Methodology
  1.3. Key Questions Answered
  1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION
  3.1. Chapter Overview
  3.2. Biopharmaceutical Excipients
  3.3. Properties of Ideal Excipients
  3.4. Classification of Biopharmaceutical Excipients
    3.4.1. Classification Based on Route of Administration
    3.4.2. Classification of Excipients Based on Structure
    3.4.3. Classification of Excipients Based on Function
    3.4.4. Classification Based on Ability to Interfere with Metabolization and Efflux Mechanisms
  3.5. Applications of Biopharmaceutical Excipients
  3.6. Regulatory Scenario
  3.7. Concluding Remarks

4. MARKET LANDSCAPE
  4.1. Chapter Overview
  4.2. Biopharmaceutical Excipient Manufacturers: Overall Market Landscape
    4.2.1. Analysis by Year of Establishment
    4.2.2. Analysis by Company Size
    4.2.3. Analysis by Location of Headquarters
    4.2.4. Analysis by Location of Biopharmaceutical Excipient Manufacturing Facilities
    4.2.5. Analysis by Type of Excipient Based on Chemical Composition
      · Carbohydrates
      · Polyols
      · Polymers
      · Proteins / Amino Acids
      · Salts
      · Lipids
      · Others
    4.2.6. Analysis by Type of Excipient Based on Function
      · Surfactants
      · Stabilizers
      · Tonicity Modifiers
      · Bulking Agents
      · Buffering Agents
      · Solubility Enhancers
      · Drug Delivery System
      · Chelators
      · Antimicrobials
      · Antioxidants
      · Others
    4.2.7. Analysis by Type of Excipient Based on Chemical Structure
      · Organic
      · Inorganic
    4.2.8. Analysis by Scale of Operation
      · Preclinical
      · Clinical
      · Commercial
    4.2.9. Analysis by Type of Formulation
      · Liquid or Parenteral
      · Solid
    4.2.10. Analysis by Type of Biologic
      · Vaccines
      · Proteins / Peptides
      · Cell Therapies
      · Antibodies
      · Blood Products
    4.2.11. Analysis by Global Regulatory Compliance
      · United States Pharmacopoeia / United States Pharmacopoeia-National Formulary
      · European Pharmacopoeia
      · Japanese Pharmacopoeia
      · British Pharmacopoeia
      · China Pharmacopoeia
      · American Chemical Society Grade
      · Indian Pharmacopoeia
      · Food Chemical Codex
      · Taiwan FDA

5. COMPANY COMPETITIVENESS ANALYSIS
  5.1. Chapter Overview
  5.2. Assumptions and Key Parameters
  5.3. Methodology
  5.4. Biopharmaceutical Excipient Manufacturers: Company Competitiveness Analysis
    5.4.1. Company Competitiveness Analysis: Small Companies
    5.4.2. Company Competitiveness Analysis: Mid-Sized Companies
    5.4.3. Company Competitiveness Analysis: Large Companies
    5.4.4. Company Competitiveness Analysis: Very Large Companies

6. COMPANY PROFILES: BIOPHARMACEUTICAL EXCIPIENT MANUFACTURERS
  6.1. Chapter Overview
  6.2. ABITEC
    6.2.1. Company Overview
    6.2.2. Biopharmaceutical Excipient Offerings
    6.2.3. Manufacturing Facilities
    6.2.4. Recent Developments and Future Outlook
  6.3. Avantor
    6.3.1. Company Overview
    6.3.2. Financial Information
    6.3.3. Biopharmaceutical Excipient Offerings
    6.3.4. Manufacturing Facilities
    6.3.5. Recent Developments and Future Outlook
  6.4. BASF Pharma
    6.4.1. Company Overview
    6.4.2. Financial Information
    6.4.3. Biopharmaceutical Excipient Offerings
    6.4.4. Manufacturing Facilities
    6.4.5. Recent Developments and Future Outlook
  6.5. Corden Pharma
    6.5.1. Company Overview
    6.5.2. Biopharmaceutical Excipient Service Offerings
    6.5.3. Manufacturing Facilities
    6.5.4. Recent Developments and Future Outlook
  6.6. DFE Pharma
    6.6.1. Company Overview
    6.6.2. Biopharmaceutical Excipient Offerings
    6.6.3. Manufacturing Facilities
    6.6.4. Recent Developments and Future Outlook
  6.7. Evonik
    6.7.1. Company Overview
    6.7.2. Financial Information
    6.7.3. Biopharmaceutical Excipient Offerings
    6.7.4. Manufacturing Facilities
    6.7.5. Recent Developments and Future Outlook
  6.8. Kirsch Pharma
    6.8.1. Company Overview
    6.8.2. Biopharmaceutical Excipient Offerings
    6.8.3. Manufacturing Facilities
    6.8.4. Recent Developments and Future Outlook
  6.9. Merck KGaA
    6.9.1. Company Overview
    6.9.2. Financial Information
    6.9.3. Biopharmaceutical Excipient Offerings
    6.9.4. Manufacturing Facilities
    6.9.5. Recent Developments and Future Outlook
  6.10. Pfanstiehl
    6.10.1. Company Overview
    6.10.2. Biopharmaceutical Excipient Offerings
    6.10.3. Manufacturing Facilities
    6.10.4. Recent Developments and Future Outlook
  6.11. Roquette
    6.11.1. Company Overview
    6.11.2. Biopharmaceutical Excipient Offerings
    6.11.3. Manufacturing Facilities
    6.11.4. Recent Developments and Future Outlook
  6.12. Spectrum Chemical Manufacturing
    6.12.1. Company Overview
    6.12.2. Biopharmaceutical Excipient Offerings
    6.12.3. Manufacturing Facilities
    6.12.4. Recent Developments and Future Outlook
  6.13. SPI Pharma
    6.13.1. Company Overview
    6.13.2. Biopharmaceutical Excipient Offerings
    6.13.3. Manufacturing Facilities
    6.13.4. Recent Developments and Future Outlook

7. PARTNERSHIPS AND COLLABORATIONS
  7.1. Chapter Overview
  7.2. Partnership Models
  7.3. Biopharmaceutical Excipients Manufacturing Market: Partnerships and Collaborations
    7.3.1. Analysis by Year of Partnership
    7.3.2. Analysis by Type of Partnership
    7.3.3. Analysis by Year and Type of Partnership
    7.3.4. Analysis by Type of Excipient
    7.3.5. Analysis by Type of Drug Molecule
    7.3.6. Most Active Players: Analysis by Number of Partnerships
    7.3.7. Analysis by Geography
      7.3.7.1. Intercontinental and Intracontinental Deals
      7.3.7.2. International and Local Deals

8. RECENT EXPANSIONS
  8.1. Chapter Overview
  8.2. Biopharmaceutical Excipient Manufacturing Market: Recent Expansions
    8.2.1. Analysis by Year of Expansion
    8.2.2. Analysis by Type of Expansion
    8.2.3. Analysis by Company Size and Location of Headquarters
    8.2.4. Analysis by Location of Expanded Facility
    8.2.5. Analysis by Type of Excipient
    8.2.6. Analysis by Type of Drug Molecule
    8.2.7. Most Active Players: Analysis by Number of Recent Expansions
    8.2.8. Geographical Analysis
      8.2.8.1. Region-wise Distribution
      8.2.8.2. Country-wise Distribution

9. CAPACITY ANALYSIS
  9.1. Chapter Overview
  9.2. Key Assumptions and Methodology
  9.3. Biopharmaceutical Excipient Manufacturing: Installed Global Capacity
    9.3.1. Analysis by Company Size
    9.3.2. Analysis by Scale of Operation
    9.3.3. Analysis by Location of Manufacturing Facility
  9.4. Concluding Remarks

10. MARKET FORECAST AND OPPORTUNITY ANALYSIS
  10.1. Chapter Overview
  10.2. Forecast Methodology and Key Assumptions
  10.3. Global Biopharmaceutical Excipient Manufacturing Market, 2022-2035
  10.4. Biopharmaceutical Excipient Manufacturing Market: Distribution by Type of Biologic, 2022 and 2035
  10.5. Biopharmaceutical Excipient Manufacturing Market: Distribution by Type of Excipient, 2022 and 2035
  10.6. Biopharmaceutical Excipient Manufacturing Market: Distribution by Company Size, 2022 and 2035
  10.7. Biopharmaceutical Excipient Manufacturing Market: Distribution by Scale of Operation, 2022 and 2035
  10.8. Biopharmaceutical Excipient Manufacturing Market: Distribution by Region, 2022 and 2035
    10.8.1. Biopharmaceutical Excipient Manufacturing Market in North America
    10.8.2. Biopharmaceutical Excipient Manufacturing Market in Europe
    10.8.3. Biopharmaceutical Excipient Manufacturing Market in Asia-Pacific
    10.8.4. Biopharmaceutical Excipient Manufacturing Market in Latin America
    10.8.5. Biopharmaceutical Excipient Manufacturing Market in Middle East and Africa
  10.9. Opportunity Analysis: Key Trends and Drivers

11. CONCLUSION AND RECOMMENDATIONS
  11.1. Chapter Overview
  11.2. Key Findings
  11.3. Strategic Recommendations
  11.4. Future Outlook

12. APPENDICES
  12.1. Appendix A: List of Abbreviations
  12.2. Appendix B: List of Tables and Figures
  12.3. Appendix C: Glossary of Terms
  12.4. Appendix D: References